Qiagen NVXTER:QIA +0.74%71 FCF Margin % is 10.59% as of Mar. 2026, which is 37% below its 10-year median of 16.80. GuruFocus rates XTER:QIA with a GF Score™ of 71/100 and a GF Value™ of €45.90 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 203 Medical Diagnostics & Research companies, Qiagen NV ranks better than 88.18% on this metric.
FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Qiagen NV's Free Cash Flow for the
three
months ended in Mar. 2026 was €45 Mil. Qiagen NV's Revenue for the
three
months ended in Mar. 2026 was €426 Mil. Therefore, Qiagen NV's FCF Margin % for the quarter that ended in Mar. 2026 was 10.59%.
The historical rank and industry rank for Qiagen NV's FCF Margin % or its related term are showing as below:
XTER:QIA'
s FCF Margin % Range Over the Past 10 Years
Min: 3.67 Med: 16.8 Max: 26.43
Current: 19.23
During the past 13 years, the highest FCF Margin % of Qiagen NV was 26.43%. The lowest was 3.67%. And the median was 16.80%.
XTER:QIA's FCF Margin % is ranked better than 88.18% of 203
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.89
vs XTER:QIA: 19.23
Qiagen NV FCF Margin % Related Terms
Qiagen NV FCF Margin % Historical Data
* Premium members only.
The historical data trend for Qiagen NV's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:QIA vs TWST, CRL, BLLN: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Qiagen NV's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Qiagen NV FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Qiagen NV's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Qiagen NV's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Qiagen NV (XTER:QIA) has a FCF Margin % of 10.59% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Qiagen NV and its competitors. This is 37% below median its historical median of 16.80. Over the past decade, Qiagen NV's FCF Margin % has ranged from 3.67 to 26.43. According to the industry distribution chart, Qiagen NV ranks #24 out of 203 companies in the Medical Diagnostics & Research industry, placing it in the top 11.8%.
Is Qiagen NV's FCF Margin % too high?
Qiagen NV's current FCF Margin % of 10.59% is 37% below median its 10-year median of 16.80. Over the past 10 years, this metric has ranged from a low of 3.67 to a high of 26.43. Based on the distribution chart, Qiagen NV ranks #24 out of 203 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Qiagen NV has a GF Score™ of 71/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Qiagen NV's FCF Margin % compare to TWST and CRL?
According to the Medical Diagnostics & Research industry distribution chart, Qiagen NV ranks #24 out of 203 companies for FCF Margin %. This places Qiagen NV in the top 12% of its industry — outperforming the majority of peers. Historically, Qiagen NV's own FCF Margin % has ranged from 3.67 to 26.43 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Qiagen NV and its competitors. Qiagen NV's current FCF Margin % is 10.59%, which is 37% below median its own 10-year median of 16.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Qiagen NV stock overvalued right now?
Based on GuruFocus' analysis, Qiagen NV (XTER:QIA) is currently considered Modestly Undervalued. The stock's GF Value™ is €45.90, compared to a current price of €34.57 — trading 24.7% below its estimated fair value. The current FCF Margin % is 10.59%, which is 37% below median its 10-year median of 16.80. Qiagen NV's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Qiagen NV (XTER:QIA), the current FCF Margin % is 10.59% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Qiagen NV (XTER:QIA) Overvalued in 2026?
Based on GuruFocus' analysis, Qiagen NV stock appears to be undervalued.
The current stock price of €34.57 is trading 24.7% below its estimated GF Value™ of €45.90.
GuruFocus considers Qiagen NV to be Modestly Undervalued.
Key valuation signals for XTER:QIA:
FCF Margin %: 10.59% (37% below median its 10-year median of 16.80)
GF Value™: €45.90 vs. price of €34.57 (24.7% below fair value)
No single metric tells the full story. See the XTER:QIA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).
71GF Score
Get the complete analysis for XTER:QIA
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:QIA has been successfully added to your 
